Rigshospitalet
Department of Radiation Biology

Lung Cancer - SCLC

Lung cancer is one of the most common types of cancer both in men and women. The disease is often divided into two types: small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

In some cases, surgery on patients with NSCLC gives good results, but similar results are not possible in the case of patients with SCLC, since this type of cancer has almost always spread in the patients. Patients must therefore be treated systemically, and in most cases they are given chemotherapy. In addition, local treatment in terms of radiotherapy is often used as a supplement to chemotherapy. Despite intensive attempts to improve treatment, and despite the fact that most patients (70-80%) respond well to begin with, the mortality rate is still high. Only a small proportion of patients with SCLC are cured (5-8%), and new knowledge about this type of cancer is therefore greatly needed, just as there is a huge need for using this knowledge to develop a new, more effective treatment.

Based on a large scale global gene expression analysis we have discovered many new potential targets for treatment of SCLC. Some of these molecules are surface receptors, which can be targeted directly. Others are genes highly and specifically expressed in the cancer cells, where the regulatory regions of the genes (promoters) can be used for transcriptional targeting of a therapeutic gene.

See Targeted Therapy for Small Cell Lung Cancer under Current Projects for a more detailed description of the projects.

 

 

The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark